About 6–8% of patients undergoing percutaneous coronary intervention (PCI) have an indication for long-term oral anticoagulants (OACs) due to various conditions such as atrial fibrillation (AF), mechanical heart valves, or venous thromboembolism.
The standard of care of management in this patients, indicated by 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease, recommends the use of a triple therapy (Aspirin, clopidogrel and OAC) for 1-6 months (depending on the ischemic and hemorrhagic risk), then continue with double therapy only up to twelve month (Aspirin or clopidogrel and OAC) and after twelve months continue with the OAC only; the use of prasugrel or ticagrelor as part of triple therapy should be avoided.
Aim of the present study is to describe the contemporary management of patients who underwent a PCI and have an indication to OACs for AF evaluating the different types of combination therapies used (triple therapy with warfarin or with direct oral anticoagulant (DOAC), single anti-platelet therapy plus warfarin or DOAC) and their management in the first year after a PCI in a “real-life” setting. Secondary we would also evaluate the safety (in term of bleedings) and the efficacy (in term of ischemic and cardioembolic events) of the use of the different combination of single or double antiplatelet with OACs, in patients with coronary artery disease.


We're not around right now. But you can send us an email and we'll get back to you, asap.


Log in with your credentials


Forgot your details?

Create Account